Development of Donor Recipient Chimeric Cells of bone marrow origin as a novel approach for tolerance induction in transplantation

Joanna Cwykiel¹,², Maria Madajka-Niemeyer², Maria Siemionow¹,²,³

¹Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL, USA; ²Department of Plastic Surgery, Cleveland Clinic, Cleveland, Ohio, USA; ³Department of Surgery, Poznan University of Medical Sciences, Poznan, Poland

Contributions: (I) Conception and design: M Siemionow; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: J Cwykiel, M Madajka-Niemeyer; (V) Data analysis and interpretation: J Cwykiel, M Madajka-Niemeyer; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Maria Siemionow, MD, PhD, DSc. Department of Orthopaedics, University of Illinois at Chicago, Molecular Biology Research Building, 900 S. Ashland Ave. Room# 3356, Chicago, IL 60607, USA. Email: siemiom@uic.edu.

Background: Cell therapies and chimerism-based strategies are currently the most successful approach for tolerance induction in transplantation. This study aimed to establish and characterize novel Donor Recipient Chimeric Cell (DRCC) therapy of bone marrow (BM) origin presenting donor-recipient phenotype to support tolerance induction.

Methods: Ex vivo fusions of fully MHC-mismatched BM cells from ACI (RT1ᵃ) and Lewis (RT1ˡ) rats were performed using polyethylene-glycol (PEG). The creation of rat DRCC was tested by flow cytometry (FC), confocal microscopy and PCR. FC characterized DRCC’s phenotype (CD3, CD4, CD8, CD45, CD90, CD11b/c, CD45RA, OX-82, or CD4/CD25) and apoptosis, while mixed lymphocyte reaction assessed DRCC’s immunogenicity and colony forming unit assay tested DRCC’s differentiation and proliferation. DRCC’s polyploidy was evaluated using Hoechst33342 staining and COMET assay tested genotoxicity of fusion procedure. ELISA analyzed the secretion of IL-2, IL-4, IL-10, TGFβ1, IFNγ and TNFα by DRCC at day 1, 5 and 14 post-fusion. The DRCC’s phenotype after long-term culturing was assessed by reverse-transcription PCR.

Results: The chimeric state of DRCC was confirmed. Fusion did not change the expression of hematopoietic markers compared to BM controls. Although an increased number of early and late apoptotic (Annexin V⁺/Sytox blue⁻ and Annexin V⁺/Sytox blue⁺, respectively) DRCC was detected at 24h post-fusion, the number significantly decreased at day 5 (38.4±3.1% and 22.6±2.5%, vs 28.3±2.5% and 13.9±2.6%, respectively, P<0.05). DRCC presented decreased immunogenicity, increased expression of IL-10 and TGFβ1 and proliferative potential comparable to BM controls. The average percentage of tetraploid DRCC was 3.1±0.2% compared to 0.96±0.1% in BM controls. The lack of damage to the DRCC’s DNA content supported the DRCC’s safety. In culture, DRCC maintained proliferation for up to 28 days while preserving hematopoietic profile.

Conclusions: This study confirmed feasibility of DRCC creation via ex vivo PEG mediated fusion. The created DRCC revealed pro-tolerogenic properties indicating potential immunomodulatory effect of DRCC therapy when applied in vivo to support tolerance induction in solid organ and vascularized composite allograft transplantation.

Keywords: Donor recipient chimeric cell (DRCC); transplantation; cell fusion; cell therapy; immunomodulation
Introduction

Despite the effort to optimize immunosuppression (IS) protocols, the morbidity associated with immunosuppressants significantly reduces transplant recipient's lifespan. Up to-date, bone marrow transplantation (BMT)/hematopoietic stem cell transplantation and induction of mixed chimerism remain the most successful approach for tolerance induction (1). However, BMT requires recipient’s conditioning excluding some of the patients in need of allotransplantation. Experimental and clinical BMT studies reported presence of donor/recipient cells and suggested their contribution to regeneration and immune response (2-14).

Cell fusion, an ubiquitous process of asexual merging of two or more parental cells (15,16), was shown to change the morphology and to reprogram the function of resulting hybrids (2). Hybrids presented increased migratory activity (17,18), proliferation (17) and drug resistance (19) as well as mixed phenotype and expression patterns (20,21). Based on these studies we aimed to develop a novel Donor Recipient Chimeric Cell (DRCC) therapy via ex vivo fusion of bone marrow cells (BMC) from transplant donor and recipient. The proposed approach of DRCC presenting mixed donor/recipient phenotype aims to create cell therapy offering decreased immunogenicity while improving DRCC engraftment and supporting tolerance induction.

This study focused on establishing and in vitro characterization of DRCC as well as comparison of DRCC with the naïve BMC in preparation for preclinical testing in solid organ and Vascularized Composite Allotransplantation (VCA) models as a basis for potential future clinical application.

We present the following article in accordance with the ARRIVE reporting checklist (available at http://dx.doi.org/10.21037/sci-2020-044).

Methods

BMC isolation

Institutional Animal Care and Use Committee (IACUC) of Cleveland Clinic, Cleveland, Ohio approved this study (License number: 2012-0841). Cleveland Clinic IACUC is accredited by the American Association for the Accreditation of Laboratory Animal Care (AAALAC). All animals received humane care in compliance with the ‘Principles of laboratory animal care’ formulated by the National Society for Medical Research and the ‘Guide for the care and use of laboratory animal resources’ published by the US National Institute of Health.

BMC were isolated from femurs and tibias harvested from randomly selected 7–8-week old male ACI (RT1a, n=30) and Lewis (RT1l, n=30) donors (Envigo, Indianapolis, IN, USA) in a sterile manner using flashing technique (22,23). Harvested cells were filtered using 40µm strainer, purified by Histopaque 1083 (MiliporeSigma, St. Louis, MO, USA) and counted with 0.4% Trypan Blue (ThermoFisher Scientific, Waltham, MA, USA).

Fusion procedure

BMC from ACI (RT1a) and Lewis (RT1l) donors were stained using PKH26 (ACI) or PKH67 (Lewis) fluorescent dyes (MiliporeSigma). Staining was performed as previously reported (22,24,25) with the adjusted staining time of 3 min. Next, PKH26 labeled ACI BMC and PKH67 labeled Lewis BMC were mixed and washed with RPMI 1640 medium without FBS. Fusion was performed as previously reported (24,25) using 50% w/v polyethylene glycol 4000 (EMD, Burlington, MA, USA) and 16% dimethyl sulfoxide (DMSO). PKH26/PKH67 labeled DRCC were selected using BD Special Order BD FACS Aria II. DRCC’s purity (1×10^5 cells, n=3) were assessed using LSRFortessa cytometer (BD, Franklin Lakes, NJ, USA). DRCC’s viability, diameter and circulatory index (n=3) were measured by Trypan blue staining with Vi-CYTO Cell Viability Analyzer (Beckman Coulter, Brea, CA, USA).

Confocal microscopy

BMC controls and DRCC were fixed in 4% paraformaldehyde (EMS, Hatfield, PA, USA) for 15 min. Images of PKH labeled cells mounted with VECTASHIELD Antifade Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA, USA) were taken by TCS-SP upright confocal microscope with Retiga 2000R camera (Leica, Wetzlar, Germany) and ImagePro Plus (Media Cybernetics, Rockville, MD, USA).

PCR

DNA was isolated using DNeasy Blood & Tissue Kit (QIAGEN, Hilden Germany USA) according to the manufacturer’s instructions. PCR (n=3) was performed as previously described (22).

Colony forming unit (CFU) assay

To assess proliferation and differentiation properties,

© Stem Cell Investigation. All rights reserved.

Stem Cell Investig 2021;8:8 | http://dx.doi.org/10.21037/sci-2020-044
BMC controls and DRCC (n=3/group) were cultured in MethoCult® medium (Stemcell Technologies, Vancouver, Canada) according to manufacturer instructions. Photographs of CFU were taken using MZ16FA stereomicroscope equipped with Retiga cooled CCD camera (Leica).

Flow cytometry

Annexin V staining (BioLegend, San Diego, CA, USA) of BMC controls and DRCC (1×10⁶, n=3/group) was performed after sorting, at 24 hours and at 5 days after sorting according to the manufacturer’s instruction (BioLegend) and evaluated by LSRFortessa and Flowjo software (BD). Gating strategy for Annexin V/Sytox blue staining evaluation was based on previously published two-stage gating strategy (26).

Phenotype analysis: BMC controls and DRCC (1×10⁶, n=3/group) blocked with Rat Fc Block (BD Biosciences, USA) for 5 min. were incubated with antibodies: CD3–APC, CD45–APC-Cy7, CD4–APC-Cy7, CD90–Pacific Blue, CD11b/c–APC (Biolegend), CD8a-BV421, CD25–APC, CD45RA–BV421 (BD Biosciences), or OX-82–Biotin (ThermoFisher Scientific) in combination with Streptavidin-APC-Cy7 (BD Pharmingen) for 40 min at 4 ℃. Cells were assessed using LSR II analyzer (BD).

Enzyme-linked immunosorbent assay (ELISA)

The medium samples from cultures of DRCC in enriched StemSpan® SFEM medium were collected at days 1, 5 and 14. ELISA was performed in triplicates to assess the secretion of IL-2, IL-4, IL-10, TGFß1, IFNγ and TNFα (ThermoFisher Scientific) according to manufacturer’s instructions. Bio-Rad iMark Microplate Absorbance Reader (Bio-Rad Laboratories, Hercules, CA, USA) was used to acquire data.

Mixed lymphocyte reaction

Splenocytes isolated from 7–8 weeks old male Lewis and BN rats (n=3/assay), were labeled with 3 μM CellTrace™ Violet and applied as responder cells (2×10⁵/assay). Stimulator cells were irradiated (3000 cGy) using a 137Cs source (Gamma cell® 3000, Ottawa, ON, Canada). Phytologam glutamin (PHA, 5 μg/mL) was used for mitogen stimulation. DRCC were seeded at concentration of 1×10⁴, 1×10⁵ and 1×10⁶ cells. Mixed responder and stimulator cells were cultured in 200 μL of “complete” RPMI 1640 medium containing 10% FBS and 1X antibiotic/antimycotic solution (1XAA, ThermoFisher Scientific) for 5 days.

Hoechst 33342 staining

To assess DRCC’s ploidy (n=3/assay), the DRCC were incubated with 10μg/mL Hoechst 33342 dye for 45 minutes at 37 ℃. Immediately after completion of staining and washing, samples were assessed by BD LSRFortessa and Flowjo software (BD).

COMET assay

COMET assay kit (Abcam, Cambridge, United Kingdom) assessed the DNA damage after cell fusion (n=3). The isolated BMC, PKH labeled BMC and DRCC were processed according to manufacturer’s instruction. Slides were assessed using MZ16FA stereomicroscope equipped with 10x and 20x objectives, Retiga 2000R camera (Leica). Fifty cells were evaluated in each gel using visual scoring system 0-4, from 0 (no tail) to 4 (all DNA in tail) with the average minimal score of 0 and average maximal of 200 “arbitrary units” (27).

DRCC culturing

DRCC (n=3) were tested in the: (I) “complete” DMEM, (II “complete” RPMI 1640, (III) StemSpan® SFEM (Stemcell Technologies) medium with 1XAA, and (IV) enriched StemSpan® SFEM medium containing 10% FBS, 1XAA and cytokine mix (28), including recombinant human acidic Fibroblast Growth Factor (aFGF, 10 ng/mL), recombinant mouse Stem Cell Factor (SCF, 10 ng/mL), recombinant mouse Thrombopoietin (TPO, 20 ng/mL), recombinant mouse Insulin Growth Factor-II (IGF-II, 20 ng/mL; R&D Systems, Minneapolis, MN), 1XAA (MiliporeSigma), Heparin (10 μg/mL, MiliporeSigma) and 10% FBS (ThermoFisher Scientific). DRCC were cultured in standard conditions for 30 days. Trypan Blue and Sytox blue tested DRCC’s number and viability.

Reverse transcription PCR

RNA from cultured DRCC (n=3) was isolated using TRIZOL® Reagent (ThermoFisher Scientific) and purified with RNeasy® Mini Kit according to the manufacturer’s instructions. Concentration and quality of RNA was tested
with NanoDrop® ND-1000 (ThermoFisher Scientific) and visual examination of 28S and 18S rRNA bands. RNA (0.65 µg) was transcribed to cDNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystem) according to manufacturer’s instruction. PCR was performed using Mastercycle epgradient PCR system (Eppendorf, Hamburg, Germany) for genes: CD11a (5’-GTTTTCAAGGCTGCTGTGG-3’, 5’-TAGCCAGACTCAACCTGCA-3’; 698bp), CD18, (5’-CTGGCCACAAACTTTGCCGA-3’, 5’-GAGACCCCTACCTGCTCCT-3’; 509 bp), Cd31 [101 bp, (29)], Cd45 (5’-GAAGACCCCTACCTGCTCCT-3’; 235bp), CD90 (5’-CCAGAGACGGACAGGTGATCA-3’, 5’-GGATGTACTGGGCCTCCACT-3’; 99bp), fibronectin (5’-CGTCAGGCTTAGGCCAAGAC-3’, 5’-TGGCTTGGAGGAAGGAGG-3’; 156bp), vimentin (5’-CCAGAGACGGACAGGTGATCA-3’, 5’-GGATGTACTGGGCCTCCACT-3’; 99bp), collagen 1A1 (5’-TGGATTCCAGTTCGAGTATG-3’, 5’-CTTCTTGCTGGTACTGCGCC-3’; 280bp), and β-actin [495bp, (30)] as reference gene. Amplification was carried out for 40 cycles in a total volume of 25 µL containing Platinum® Blue PCR SuperMix (ThermoFisher Scientific), primers (0.2 µM) and 0.2 µg cDNA in standard conditions.

Statistical analysis

Statistical analysis was performed using Minitab software (OriginLab Corp. Northhampton, MA, USA). In vitro assays were performed in triplicates in three independent experiments with naïve and/or PKH labeled BMC as reference controls. Values are presented as mean ± SD. One-way ANOVA and general linear model followed by Tukey’s post-hoc tests or Student T-test determined statistical significance at P<0.05.

Results

Confirmation of DRCC Creation

The fusion procedure in combination with gating strategy allowed for selection of DRCC with efficacy of 77.7%±9.1%. The DRCC’s chimeric state was confirmed using the overlapping PKH26/PKH67 labeling by confocal microscopy and the presence of MHC class I sequences specific for ACI (RT1’') and Lewis (RT1’’) donors in the DNA material of sorted DRCC (Figure 1A,B,C). DRCC presented >95% purity, as confirmed by flow cytometry and 95.2%±2.3% viability post-fusion, as confirmed by Trypan blue staining.

Evaluation of apoptosis in cultured DRCC

Annexin V staining, a marker of early apoptosis (Annexin V+/Sytox blue−) showed no changes among the assessed samples of unstained ACI (8.32%±1.54%) and Lewis BMC (7.43%±1.4%), PKH26 labeled ACI (8.4%±0.95%) and PKH67 labeled Lewis BMC (7.74%±1.7%) and DRCC (8.02%±1.4%) at the fusion day (Figure 1D). At 24 h post-fusion the percentage of Annexin V+/Sytox blue− cells doubled in unstained ACI (14.8%±3%) and Lewis BMC (18.3%±2.6%, P<0.003 vs. 0 h), PKH26 labeled ACI (11.3%±1.6%) and PKH67 labeled Lewis BMC (16.4%±3.2%, P<0.04 vs. 0 h). The percentage of Annexin V−/Sytox blue− DRCC also increased to 38.4±3.1% (P<0.001). Decrease in the number of early apoptotic DRCC to 28.3%±2.5% (P<0.006 vs. 24 h) was observed after 5-day culture and was comparable to levels of apoptosis in samples of unstained ACI (20.9%±3.55%, P<0.004 vs. 24 h) and Lewis BMC (25.3%±2.3%, P<0.02 vs. 24 h) as well as PKH26 labeled ACI (21.4%±2.32%, P<0.0008 vs. 24 h) and PKH67 labeled Lewis BMC (25.2%±3.95%, P<0.04 vs. 24 h).

Annexin V−/Sytox blue− staining (Figure 1E) showed an increase in the number of late apoptotic cells after PKH26 and PKH67 BMC staining and fusion (3.55%±1.3%, 4.8%±1.5% and 5.78%±1.2%, respectively), compared to unstained ACI and Lewis BMC (1.6%±0.96%* and 1.9%±1.1%*, respectively; P<0.02 vs. DRCC). After 24-hour culturing, the number of late apoptotic cells significantly increased in samples of unstained ACI (13.6%±1.4%*, P<0.02 vs. DRCC) and Lewis BMC (14.5%±2.5%*, P<0.03 vs. DRCC) as well as PKH26 labeled ACI (17.7%±3.1%*) and PKH67 labeled Lewis (15.4%±3.6%*) BMC and DRCC (22.6%±2.5%*, *P<0.001 vs. 0 h). After 5-day culturing the late apoptotic cells number decreased in all samples (unstained ACI BMC 3.6%±1.2%*, unstained Lewis BMC 6%±4.6%*, PKH26 labeled ACI BMC 5.7%±1.8%*, and PKH67 labeled Lewis BMC 5.3%±2.4%* and DRCC 13.9%±2.6%; *P<0.04 vs. DRCC) compared to results obtained at 24h (P<0.04).

Confirmation of hematopoietic phenotype of DRCC

The average BMC diameters were 8.9±0.14 µm for
Figure 1 Confirmation of the chimeric state and viability of Donor Recipient Chimeric Cells (DRCC). (A) Representative plots of (from left): isolated Lewis donor bone marrow cells (BMC), isolated ACI donor BMC, PKH67 labeled Lewis donor BMC, PKH26 labeled ACI donor BMC and DRCC after fusion. The overlapping fluorescence of PKH26/PKH67 confirms chimeric state of DRCC. (B) Fluorescence images confirming creation of DRCC via cell fusion; From left: isolated Lewis donor BMC, isolated ACI donor BMC, PKH67 labeled Lewis donor BMC, PKH26 labeled ACI donor BMC and DRCC after fusion. For merge: Green: PKH67; Red: PKH26; Blue: DAPI (nuclei); Magnification 63X, scale bars 10 µm. (C) Confirmation of the chimeric state of DRCC by polymerase chain reaction (PCR) (22). PCR tested the presence of MHC class I sequences specific for Lewis (RT1<sup>a</sup>; 448bp) and ACI (RT1<sup>l</sup>; 388bp) donors in the DNA isolated from DRCC. From left: column 1: marker, column 2: RT1<sup>a</sup> sequence detected in the DRCC’s DNA and column 3: RT1<sup>l</sup> sequence detected in the DRCC’s DNA. Glyceraldehyde 3-phosphate dehydrogenase (Gapdh, 197bp) served as an internal control (n=3). (D) Analysis of Annexin V<sup>+</sup>/Sytox blue<sup>+</sup> (E) Annexin V<sup>+</sup>/Sytox blue<sup>−</sup> staining in isolated ACI BMC, isolated Lewis BMC, PKH26 labeled ACI BMC, PKH67 labeled Lewis BMC and DRCC at the day of fusion, 24 h and 5 days after fusion (n=3/group/timepoint). A significant decrease in the number of Annexin V<sup>+</sup>/Sytox blue<sup>+</sup> and Annexin V<sup>+</sup>/Sytox blue<sup>−</sup> DRCC was observed after 5-day culture compared to DRCC at 24 h post-fusion (P<0.01 and P<0.05, respectively). (F) Comparison of the average diameter of cell prior and after ex vivo cell fusion. The average diameter of DRCC increased (9.3±0.08 µm; P<0.05) compared to isolated BMC (ACI 8.9±0.14 µm, Lewis 9±0.15 µm) and BMC labeled with PKH dyes (PKH26 labeled ACI 8.98±0.11 µm, PKH67 labeled Lewis 8.9±0.22 µm). *P<0.05, **P<0.01, ***P<0.001.
unstained ACI, 9±0.15 μm for unstained Lewis BMC, 8.98±0.11 μm for PKH26 labeled ACI and 8.9±0.22 μm for PKH67 labeled Lewis BMC, while the average diameter of DRCC was 9.3±0.08 μm (P<0.05, Figure 1F). This result was in line with a shift of forward (FSC) vs. side scatter (SSC) plots of BMC prior to and after fusion. There was no statistically significant change in circularity index between the BMC controls and DRCC.

Phenotype characterization confirmed the low number of CD3 (<1%), CD4 (<7%) and CD8 (<1%) positive cells within DRCC population (Figure 2A,B). DRCC presented 98.2%±1.9% of CD45 and 46.4%±2.06% of CD90 positive cells. The average expression of CD11b/c was 25%±2.45%, CD45RA was 28.3%±1.2% and OX-82 was 13.3%±2.6%. The percentage of CD4/CD25 positive DRCC was 3.2±0.84. No statistically significant differences were observed in the expression patterns of the assessed markers between BMC controls and DRCC (Figure 2B).

**Confirmation of DRCC’s proliferation and differentiation**

CFU assay confirmed that DRCC can produce the same types (Figure 2C) and comparable number of colonies as BMC controls. The average total number of colonies produced by unstained BMC was 63.2±19.7 (Lewis) and 83.8±30.9 (ACI), PKH67 labeled Lewis BMC was 63.6±21, PKH26 labeled ACI BMC was 74.8±27 and DRCC was 56.2±6.6 (P>0.05). Following CFU assay, 79% of DRCC presented immature progenitor granulocyte/macrophage phenotype, as confirmed by CD90 and CD11b/c staining, and MHC class I specific for fusion donors was present in DRCC derived DNA (Figure 2D,E).

**Confirmation of tolerogenic properties of DRCC**

MLR assay showed significantly lower (7.8%±1.54%) response to DRCC compared to controls stimulated by PHA (60.2%±9.08%) and the 3rd party allogenic T-cells (57.23%±4.44%, P<0.05, Figure 3A,B,C,D,E). The autologous T-cells control using irradiated Lewis T-lymphocytes showed 2.88%±1.27% proliferation rate.

**DRCC secretes pro-tolerogenic IL-10 and TGFβ1**

ELISA confirmed that DRCC secrete IL-10 at levels of 16.79±0.46 pg/mL at 24 h, 31.47±0.4 pg/mL at 5 days and 11.58±0.15 pg/mL at 14 days, as compared to medium (3.09±1.95 pg/mL) and BMC controls (16.4±0.75 pg/mL). The DRCC’s secretion of TGFβ1 reached 129.8±13.2 pg/mL at 24 h, 139.5±12.56 pg/mL at 5 days and 185.2±5.2 pg/mL at 14 days and increased significantly compared to the medium (108.1±13.2 pg/mL) and BMC (109.5±14.7 pg/mL) controls (Figure 3F). The elevated level of TGFβ1 detected in the medium control is due to the presence of FBS in the enriched StemSpan® SFEM medium. FBS contains a high level of latent TGFβ, which is detected by ELISA assay. Latent TGFβ does not bind to TGFβ receptors (31). ELISA did not detect IL-2, TNFα, IFNγ or IL-4 in any of collected samples.

**Confirmation of low polyploidy of DRCC**

Hoechst33342 indicated that the average percent of tetraploid (4N) DRCC was 3.1%±0.2% compared to isolated BMC (0.96%±0.1%, Figure 4A). The low occurrence rate of multinucleated cells was also detected by confocal microscopy post-fusion (Figure 1B).

**COMET assay confirms lack of DNA damage post-fusion**

Visual scoring of COMET assay of ACI and Lewis BMC, PKH26 labeled ACI and PKH67 labeled Lewis BMC, and DRCC showed negligible number of cells scored as 1 (0.2±0.4, 0.3±0.7, 0.1±0.7, 0.2±0.4 and 0.1±0.3, respectively) compared to BMC control pre-treated with 20µM etoposide (167±19.4, P<0.01, Figure 4B). The representative fluorescent images of COMET assay performed in alkaline solution of the etoposide pre-treated BMC control (positive control), ACI and Lewis BMC, PKH26 labeled ACI and PKH67 labeled Lewis BMC, and DRCC are presented in Figure 4C confirming no damage to the DNA of either BMC prior to fusion as well as DRCC after fusion procedure.

**DRCC cultures**

In all of the tested media >80% of DRCC remained non-adherent to the plastic. DRCC survived 14–18 days in the StemSpan® SFEM medium without FBS, 16–21 days in “complete” DMEM and RPMI media and 26–28 days in the enriched StemSpan® SFEM medium. The enriched StemSpan® SFEM medium presented the lowest percentage of necrotic DRCC (13.9%±2.6%, P<0.05) at day 5 of culturing compared to 26.5%±6.8% of necrotic DRCC in “complete” DMEM, 25.6%±1.9% in “complete” RPMI and 33.6%±4.6% in Stemspect® SFEM medium (n=3/group). The DRCC reached plateau at day 12 of culturing.
Figure 2 Confirmation of the maintenance of hematopoietic phenotype and preservation of proliferation and differentiation properties of Donor Recipient Chimeric Cells (DRCC) after ex vivo cell fusion. (A) Representative histograms presenting expression of CD3, CD4 and CD8 markers of T-cells, CD90 marker of progenitor cells, CD11b/c marker of monocytes, CD45RA marker of B cells, OX-82 marker of myeloid cells, CD4/CD25 marker of T regulatory cells (blue histograms) expressed on the surface of DRCC superimposed on unstained control samples (red histograms). (B) Comparison of the average percentage of CD3, CD4, CD8, CD45, CD90, CD11b/c, CD45RA, OX-82 and CD4/CD25 populations among isolated BMC, PKH labeled BMC and DRCC after the ex vivo fusion procedure (n=3/group). The analysis confirmed maintenance of the percentage of Treg cell population before and after ex vivo cell fusion. (C) Characterization of proliferation and differentiation ability of DRCC using colony forming unit (CFU) assay. No differences in the morphology of granulocyte, macrophage and granulocyte/macrophage colony forming units (CFU) of isolated BMC, PKH labeled BMC and DRCC were observed after 14-day culturing. Magnification: 5X. (D) Flow cytometry plot of DRCC after CFU assay (red) co-stained for markers of progenitor cells (CD90) and granulocytes/ macrophages (CD11b/c) superimposed on a dot plot of unstained DRCC after CFU assay (blue). This result confirmed the ability of DRCC to differentiate and present granulocyte/ macrophage phenotype of observed CFU-G, CFU-M and CFU-GM colonies. (E) Confirmation of maintenance of donor-recipient (ACI/Lewis) phenotype by DRCC after CFU assay by polymerase chain reaction (PCR). From left: column 1: marker, column 2: RT1a (388bp) sequence detected in the DNA isolated from the DRCC after CFU assay, and column 3: RT1l (448bp) sequence detected in the DNA isolated from the DRCC after CFU assay, (n=3).
which was followed by decrease in the number of cells up to day 28 of the culture (Figure 4D). After 5-day culturing >80% of DRCC presented strong PKH26/PKH67 labeling sufficient to distinguish DRCC from unstained cells (Figure 4E). Strong expression of CD90, CD31, CD45, CD18 and CD11a confirmed preservation of DRCC’s hematopoietic progenitor/stem cell profile (Figure 4F).

Discussion

Multiple studies described involvement of cell fusion in tissue regeneration (6,12,24,25,32,33) encouraging development of fusion-based cell lines and therapies for research and clinical applications (2,34-40). The presence of donor/recipient cells observed in the clinical BMT studies (41-43) was explained by spontaneous fusion of donor HSC with cells of BMT recipient or by trogocytosis, a process of intercellular transfer of membrane patches or proteins (44-47). Trogocytosis modifies function of stem, progenitor and differentiated immune cells (48-51), including transfer of antigens Fc receptors or major histocompatibility complex (MHC) molecules from macrophages to lymphocytes (44,52), capture of recipient’s MHC by donor thymocytes (53,54), and transfer of MHC from recipient’s splenocytes to donor T-cells (55). The presence of hematopoietic cells presenting the donor and recipient MHC class I molecules was observed by Siemionow’s group in a rat BMT model (23,56). These donor/recipient cells created \textit{in vivo} were used to induce tolerance in a hemiface allotransplantation model. Although, the therapy provided promising results by extending the
Figure 4 Assessment of polyploidy and DNA integrity of Donor Recipient Chimeric Cells (DRCC) and characterization of DRCC after long-term culturing. (A) Representative histograms Hoechst 33342 staining comparing the polyploidy of: (from left) isolated BMC and DRCC. The isolated BMC samples contained 0.96±0.1% of tetraploid cells (4N) and in comparison, the majority of DRCC (>86%) were diploid (2N) while the 4N cells constituted 3.1±0.2%. 2N: diploid cells, S: DNA synthesis, 4N: tetraploid cells. (B) The quantitative analysis of Comet assay (Single Cell Gel Electrophoresis – SCGE assay) confirming lack of genotoxicity by absence of DNA damage in DRCC following ex vivo cell fusion procedure. The visual scoring analysis of the Comet assay tails proved the absence of genotoxicity of cell fusion procedure on BMC and DRCC, \( *P<0.05 \). Rat naïve BMC treated with 20 µM etoposide overnight served as positive controls. (C) Representative fluorescence images of Comet assay showing DNA damage in 20 µM etoposide treated BMC (positive controls) and confirming lack of DNA damage in isolated ACI and Lewis BMC controls, PKH labeled ACI and Lewis BMC controls and DRCC. Green - Vista Green DNA Staining Solution (nucleus stain); Magnification 10× and 20×, scale bars 10 µm. (D) Analysis of proliferation kinetics of DRCC cultured in enriched Stemspan® SFEM medium. Absolute cell counts (n = 3) at each timepoint were normalized with the number of seeded cell and proliferation was expressed in the fold increase. DRCC confirmed statistically significant maximal proliferation counts at day 12 after fusion (\( *P<0.05 \)). (E) Flow cytometry plot confirming the maintenance of PKH26/PKH67 labeling of DRCC after 5-day culturing in enriched Stemspan® SFEM medium. (F) Comparison of hematopoietic and stromal cell markers expressed by DRCC after 5-day culturing in enriched Stemspan® SFEM medium as assessed by reverse transcription polymerase chain reaction (rt-PCR). Representative images of PCR products of progenitor cells marker: CD90, CD31, hematopoietic cells markers: CD45, CD11a, CD18 and stromal cells markers: fibronectin (FN), vimentin (VIM), and Collagen 1a1 (Col1a1). M: marker of the PCR reaction product size, 1: RNA control; 2: cDNA from cultured DRCC, actB: beta actin served as a reference gene for the PCR reaction.
in vivo survival, the technique of obtaining DRCC was not clinically applicable. Thus, we applied ex vivo cell fusion to create DRCC therapy to facilitate allograft-specific tolerance.

In our proof of concept study, the feasibility of cell fusion procedure and creation of DRCC were confirmed based on fluorescence tracing dyes and the presence of genomic MHC class I sequences specific for each BMC donor. We established fusion protocol for DRCC creation achieving 77.7% ±9.1% efficiency with >95% purity and >90% viability. As expected, fusion increased the average DRCC diameter but did not affect DRCC circularity.

The increased percentage of Annexin V+/Sytox blue- and Annexin V-/Sytox blue’ DRCC at 24h after fusion compared to BMC controls could have resulted from DRCC processing time, sorting conditions, or application of PEG/DMSO fusion solution (57). However, at day 5 of culturing, the number of early apoptotic DRCC (Annexin V-/Sytox blue') decreased and was comparable to BMC controls. The recovery of DRCC population and DRCC’s capability for differentiation in vitro were supported by the CFU assay results. This suggests capability of DRCC for engraftment and chimerism induction in vivo. Evaluation of DRCC proliferative potential in long-term cultures indicated that in contrast to hybridoma cells and tumor cell lines presenting uncontrollable proliferation (58,59), DRCC exhibited limited number of cell divisions.

The phenotype comparison between BMC controls and DRCC proved that ex vivo fusion does not change the values of lymphoid and myeloid markers with DRCC characterized predominantly by hematopoietic (CD45) stem/progenitor cells (CD90), expressing myeloid (CD11b/ c, OX-82) and B cell markers (CD45RA). This indicates the capability of DRCC to generate multilineage chimerism in vivo comparable to BMT.

DRCC’s presented pro-tolerogenic properties with increased secretion of pro-tolerogenic cytokines IL-10 and TGFβ1 and lack of Th1 inflammatory cytokines. IL-10 and TGFβ participate in multiple regulatory processes by stimulation of Treg, Breg, monocytes/macrophages and DC (60). IL-10 decreases expression of MHC-II, costimulatory molecules and IL-12 while TGFβ reduces lymphocyte proliferation and deactivation of killer T-cells (61,62).

DRCC presented significantly lower immunogenicity compared to PHA and allogenic cell controls. Any transplanted cells which are not identical to the recipient, have potential to trigger the recipient’s immune response (63). Thus, despite its’ low immunogenicity, DRCC still may initiate the recipient’s immune response in vivo. Therefore, introduction of short-term IS may be required during in vivo DRCC testing. The immature phenotype of DRCC combined with low immunogenicity and secretion of IL-10 and TGFβ1, confirms pro-tolerogenic profile of DRCC population which suggests that in vivo DRCC may have the ability to avoid the immune cells’ recognition and engraft more efficiently without recipient’s conditioning.

Although PEG is a nonmutagenic compound (64) inhibiting oncogenesis (65,66), the safety of DRCC was assessed based on DRCC ploidy and potential damage to DRCC’s DNA. DRCC presented low frequency of tetraploid cells (4N: 3.1%±0.2%). No multinucleated DRCC (>4N) were observed following fusion procedure. Cells presenting higher DNA ploidy have been reported in studies exploring fusion created tumor cells and were associated with problems with irregular and unrestricted cell proliferation (67). The diploid state of the majority of the DRCC (2N >96%) combined with the lack of synkaryons or polyploidy exceeding 4N adds to the safety profile of DRCC for in vivo application. Moreover, negligible degradation of the DNA material during the visual COMET scoring demonstrated limited genotoxicity of fusion procedure.

Cytokine enriched StemSpan® SFEM medium (28) supported the longest DRCC survival with a six-fold cell number increase. Cytokines were added to the medium to prevent apoptosis and stimulate the symmetric self-renewal of DRCC stem cells in long-term cultures (68-72). Moreover, the enriched medium allowed DRCC to maintain hematopoietic phenotype. Based on the DRCC growth phase, proliferation rate and the peak of the pro-tolerogenic cytokine expression, the 5-day of DRCC culturing was selected as optimal for DRCC harvesting and application as a tolerance inducing therapy.

This study confirmed both, the feasibility of DRCC creation via ex vivo cell fusion as well as highlighted the pro-tolerogenic properties of DRCC in vitro. The pro-tolerogenic DRCC profile in combination with DRCC proliferation and differentiation potential which is comparable to BMC will facilitate engraftment and survival of DRCC in vivo. This proof-of-concept study provides basis for future in vivo testing of the immunomodulatory effects of DRCC therapy in preclinical experimental transplantation models.

**Conclusions**

This study established and characterized a novel hematopoietic donor/recipient specific DRCC. Due to
decreased immunogenicity and pro-tolerogenic cytokine expression, DRCC represent a promising approach as a personalized supportive therapy for the chimerism and tolerance induction in BMT, solid organ and VCA transplantation.

Acknowledgments

The authors thank Aleksandra Klimczak PhD, Adam Bobkiewicz MD, PhD, Arkadiusz Jundzill MD, PhD, and Cleveland Clinic flow cytometry and imaging cores for technical support in the study.

Funding: This work was supported by funding from Department of Defense Armed Force Institute of Regenerative Medicine (AFIRM, W81XWH-08-2-0034).

Footnote

Reporting Checklist: The authors have completed the ARRIVE reporting checklist. Available at http://dx.doi.org/10.21037/sci-2020-044

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/sci-2020-044). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Experiments were performed under a project license (NO.: 2012-0841) granted by Institutional Animal Care and Use Committee (IACUC) of Cleveland Clinic, in compliance with ‘Principles of laboratory animal care’ formulated by the National Society for Medical Research and the ‘Guide for the care and use of laboratory animal resources’ formulated by the US NIH guidelines for the care and use of animals.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


68. Matsunaga T, Kato T, Miyazaki H, et al. Thrombopoietin promotes the survival of murine hematopoietic long-term...

do: 10.21037/sci-2020-044

Cite this article as: Cwykiel J, Madajka-Niemeyer M, Siemionow M. Development of Donor Recipient Chimeric Cells of bone marrow origin as a novel approach for tolerance induction in transplantation. Stem Cell Investig 2021;8:8.